JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization

NCT ID: NCT05064540

Last Updated: 2025-06-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

450 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-09-20

Study Completion Date

2031-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prospective, randomized, multi-center study designed to evaluate the outcomes of commercially available contemporary EVAR in a real-world population. Patients will be randomized into two device cohorts and compared across the primary endpoints.

Patients will be followed procedurally to discharge, at 1, 6, 12 months and annually through to 5 years (total follow-up commitment).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

AAA AAA - Abdominal Aortic Aneurysm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Alto Abdominal Stent Graft System

Subjects randomized to receive the Endologix Alto Abdominal Stent Graft System for implantation to repair Abdominal Aortic Aneurysm.

Group Type EXPERIMENTAL

Alto Abdominal Stent Graft System

Intervention Type DEVICE

Endovascular Abdominal Aneurysm Repair (EVAR) using commercially available, FDA approved endovascular graft systems implanted.

Comparators

Subjects randomized to receive the comparator AAA Endovascular Graft System for implantation to repair Abdominal Aortic Aneurysm.

Group Type ACTIVE_COMPARATOR

FDA Approved EVAR AAA Graft Systems

Intervention Type DEVICE

FDA approved comparator of choice

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Alto Abdominal Stent Graft System

Endovascular Abdominal Aneurysm Repair (EVAR) using commercially available, FDA approved endovascular graft systems implanted.

Intervention Type DEVICE

FDA Approved EVAR AAA Graft Systems

FDA approved comparator of choice

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult age 21 and older
* Subjects with minimum of 2 year life expectancy
* Subjects have signed the informed consent document
* Subjects with unruptured infrarenal AAA who are assessed by the Investigator to be eligible for endovascular Abdominal Aortic Aneurysm Repair with the trial devices.
* Patient must be able and willing to comply with all required follow-up exams.

Exclusion Criteria

* Currently participating in another trial where the primary endpoint has not been reached yet.
* Known allergy to any of the device components
* Pregnant (females of childbearing potential only)
* Known connective tissue disorders
* Known active infection
* Subjects with pre-existing EVAR, i.e., in need of repair/intervention of a previously failed EVAR.
* Patient has other medical, social, or psychological conditions that, in the opinion of the investigator, preclude them from receiving the pre-treatment, required treatment, and post-treatment procedures and evaluations.
Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Endologix

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sean Lyden, MD

Role: PRINCIPAL_INVESTIGATOR

The Cleveland Clinic

Christopher Kwolek, MD

Role: PRINCIPAL_INVESTIGATOR

Newton-Wellesley Hospital

Hence Verhagen, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Erasmus University Study Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Huntsville Hospital

Huntsville, Alabama, United States

Site Status ACTIVE_NOT_RECRUITING

University of Arizona

Tucson, Arizona, United States

Site Status RECRUITING

Washington Regional Medical Center

Fayetteville, Arkansas, United States

Site Status RECRUITING

Central Arkansas Veterans Healthcare System

Little Rock, Arkansas, United States

Site Status RECRUITING

The Regents of the University of California, San Diego

La Jolla, California, United States

Site Status RECRUITING

Veterans Affairs San Diego Healthcare System

San Diego, California, United States

Site Status RECRUITING

MedStar Washington Hospital Center

Washington D.C., District of Columbia, United States

Site Status RECRUITING

Jacksonville Center for Clinical Research

Jacksonville, Florida, United States

Site Status RECRUITING

Radiology and Imaging Specialists

Lakeland, Florida, United States

Site Status RECRUITING

Baptist Hospital of Miami, Miami Cardiac and Vascular Institute

Miami, Florida, United States

Site Status RECRUITING

University of Iowa Hospitals and Clinics

Iowa City, Iowa, United States

Site Status ACTIVE_NOT_RECRUITING

University of Louisville

Louisville, Kentucky, United States

Site Status RECRUITING

Tufts Medical Center

Boston, Massachusetts, United States

Site Status RECRUITING

Henry Ford Hospital

Detroit, Michigan, United States

Site Status WITHDRAWN

University of Missouri

Columbia, Missouri, United States

Site Status RECRUITING

Newark Beth Israel Medical Center

Newark, New Jersey, United States

Site Status RECRUITING

Icahn School of Medicine at Mount Sinai

New York, New York, United States

Site Status RECRUITING

Feinstein Institutes for Medical Research (Staten Island University Hospital/Northwell Health)

Staten Island, New York, United States

Site Status RECRUITING

The Cleveland Clinical Foundation

Cleveland, Ohio, United States

Site Status RECRUITING

The Ohio State University

Columbus, Ohio, United States

Site Status WITHDRAWN

Oregon Health Sciences University

Portland, Oregon, United States

Site Status RECRUITING

U.S. Department of Veterans Affairs, VA Portland Health Care System

Portland, Oregon, United States

Site Status RECRUITING

Lehigh Valley Health Network

Allentown, Pennsylvania, United States

Site Status RECRUITING

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Site Status RECRUITING

Allegheny Health Network

Pittsburgh, Pennsylvania, United States

Site Status RECRUITING

Wellmont Cardiology Services

Kingsport, Tennessee, United States

Site Status RECRUITING

The University of Texas Medical Branch at Galveston

Galveston, Texas, United States

Site Status RECRUITING

Houston Methodist Research Institute

Houston, Texas, United States

Site Status RECRUITING

Sentara Hospitals

Norfolk, Virginia, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Noel DeSisto

Role: CONTACT

864-270-8524

Sanjana Tabassum

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Karen Sanchez

Role: primary

Callie McQueen

Role: primary

479-463-7858

Sandra Brock

Role: primary

501-257-6906

Kathleen Groh

Role: primary

951-595-2347

Annalicia Vargas

Role: primary

Kassaye Sesaba

Role: primary

202-877-7452

Lisa Joseph

Role: primary

904-732-2217

Eve Johnson

Role: primary

863-688-2334 ext. 135

David Fernandez

Role: primary

786-596-5392

Mikaela Bearham

Role: backup

786-596-4079

Leslie Haysley

Role: primary

502-852-2801

Gaurav Das

Role: primary

617-636-4990

Jennifer Randolph

Role: primary

573-882-4387

Debra Cook

Role: primary

Jack Waitz

Role: primary

212-241-8250

Alexandra Pantea

Role: primary

718-226-6438

Shannen Belotte

Role: backup

718-226-8559

Larissa Schaaf, RN

Role: primary

216-445-4437

Amie Lorisch

Role: primary

Jin Kim

Role: primary

Rachel Nelson

Role: backup

503-220-8262 ext. 58388

Deborah Mankos

Role: primary

610-402-1635

Thomas Hebert

Role: primary

973-454-3066

Sheila Bernardini

Role: primary

Joshua Lester

Role: primary

Sana Malik

Role: primary

409-747-7333

Solange Basagoitia

Role: primary

713-441-0176

Kara Wiggins, MSN, RN

Role: primary

757-388-7511

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CP-0017

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The Boston Scientific ENOVUS Trial
NCT00246038 WITHDRAWN PHASE2
Thoracoabdominal Aortic Aneurysms
NCT06267573 NOT_YET_RECRUITING
Clinical Study of Aneurysm Exclusion
NCT00549380 UNKNOWN PHASE1